Pfizer (PFE), a big name in the pharmaceutical industry and a member of the S&P 500 Index ($SPX), has been grabbing some positive attention lately. After a lengthy period of post-COVID underperformance, this dividend stalwart is showing signs of a comeback that’s catching the eye of value-minded investors. The company recently reported positive results from a late-stage trial of its gene therapy for hemophilia A, adding to the bullish buzz around its progress with an oral obesity drug. These breakthroughs have helped to push Pfizer’s stock up nearly 22% from its late-April lows. And for income…